| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/06/2004 | US6673379 Use of non-alkalized cocoa solids in a drink |
| 01/06/2004 | US6673377 Extracts derived from Pueraria mirifica, Butea superba and/or Mucuna collettii and extraction thereof |
| 01/06/2004 | CA2301990C New substitute dimerized derivatives, process for preparing them, and pharmaceutical compounds containing them |
| 01/06/2004 | CA2292629C Composition comprising 5-¬4-¬2-(n-methyl-n-2-pyridyl)amino)ethoxy|benzyl|thiazolidine-2,4-dione |
| 01/02/2004 | EP1375516A2 Method of production of a recombinant polypeptide of the LSR receptor |
| 01/02/2004 | EP1375500A1 Isoquinuclidine derivative, process for producing the same, and medicinal composition containing the same |
| 01/02/2004 | EP1375499A1 Process for the production of 2-(5-methyl-4-oxazolyl)ethanol derivatives |
| 01/02/2004 | EP1375496A1 N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient |
| 01/02/2004 | EP1375484A1 Carboxylic acids |
| 01/02/2004 | EP1375472A1 Benzene compound and salt thereof |
| 01/02/2004 | EP1375465A1 Cyclooctanone derivative and cyclodecanone derivative, and use thereof |
| 01/02/2004 | EP1374869A1 Novel use of arylethene sulfonamide derivative |
| 01/02/2004 | EP1374868A1 Remedies and/or preventives for diabetic ischemic heart diseases |
| 01/02/2004 | EP1373893A2 Phosphoprotein target for insulin and its antagonists |
| 01/02/2004 | EP1373517A2 Human kinases |
| 01/02/2004 | EP1373506A2 Yeast strain of saccharomyces cerevisiae with functional expression of a glut transporter |
| 01/02/2004 | EP1373489A2 Human dual specificity protein phosphatase 7-like protein |
| 01/02/2004 | EP1373319A2 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders |
| 01/02/2004 | EP1373317A2 Nuclear hormone receptor ligand binding domains |
| 01/02/2004 | EP1373316A2 Nuclear hormone receptor ligand binding domain |
| 01/02/2004 | EP1373315A2 Nuclear hormone receptor ligand binding domain |
| 01/02/2004 | EP1373313A2 Proteins and nucleic acids encoding same |
| 01/02/2004 | EP1373312A1 Shellfish protein |
| 01/02/2004 | EP1373287A1 Process for obtaining lignan, pharmaceutical compositions and uses thereof |
| 01/02/2004 | EP1373269A1 Jun kinase inhibitors |
| 01/02/2004 | EP1373266A2 (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes |
| 01/02/2004 | EP1373265A1 Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligands |
| 01/02/2004 | EP1373263A1 Heterocyclic compounds for aging-related and diabetic vascular complications |
| 01/02/2004 | EP1373259A1 Pyridazinone aldose reductase inhibitors |
| 01/02/2004 | EP1373258A1 Ether derivatives useful as inhibitors of pde4 isozymes |
| 01/02/2004 | EP1373257A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 01/02/2004 | EP1373251A2 Non-imidazole compounds as histamine h3 antagonists |
| 01/02/2004 | EP1373249A1 Imidazolidine derivatives, their preparation, and their use as antinflamatory agent |
| 01/02/2004 | EP1373242A1 Dimeric isoflavones |
| 01/02/2004 | EP1373240A2 Retinoid x receptor modulators |
| 01/02/2004 | EP1373233A1 Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same |
| 01/02/2004 | EP1373219A1 Thiohydantoins and use thereof for treating diabetes |
| 01/02/2004 | EP1373216A1 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 01/02/2004 | EP1373205A1 Novel piperidine derivatives as modulators of chemokine receptors |
| 01/02/2004 | EP1373203A1 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors |
| 01/02/2004 | EP1373202A1 Preparation of non-crystalline atorvastatin calcium |
| 01/02/2004 | EP1373191A1 Acylated indanyl amines and their use as pharmaceuticals |
| 01/02/2004 | EP1373185A2 Hydrophobic polyamine analogs and methods for their use |
| 01/02/2004 | EP1373182A1 Conjugated unsaturated glyceride mixtures and a method for producing the same |
| 01/02/2004 | EP1372735A2 Conjugate of hydroxyalkyl starch and an active agent |
| 01/02/2004 | EP1372726A1 Methods for reducing fat by administration of adiponectin |
| 01/02/2004 | EP1372725A1 Compositions and methods for non-insulin glucose uptake |
| 01/02/2004 | EP1372696A2 Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 01/02/2004 | EP1372695A2 Cell damage inhibitor |
| 01/02/2004 | EP1372690A2 93870, a human g-protein coupled receptor and uses therefor |
| 01/02/2004 | EP1372688A2 Somatostatin antagonists |
| 01/02/2004 | EP1372673A2 The use of non-digestible polymeric foams to sequester ingested materials, thereby inhibiting their absorption by the body |
| 01/02/2004 | EP1372664A1 Use of certain steroids for treatment of blood cell deficiencies |
| 01/02/2004 | EP1372660A2 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| 01/02/2004 | EP1372656A1 Pyrazolo[4,3-d]pyrimidinone compounds as cgmp pde inhibitors |
| 01/02/2004 | EP1372653A2 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 01/02/2004 | EP1372647A2 Use of substituted imidazo 1,2-a]-pyridine compounds as medicaments |
| 01/02/2004 | EP1372646A2 Use of sugar phosphates, sugar phosphate analogues, amino acids, amino acid analoges for modulating transaminases and/or the association of p36/malate dehydrogenase |
| 01/02/2004 | EP1372644A2 Use of substituted imidazo 1,2-a]-pyridine-3-yl-amide and imidazo 1,2-a]-pyridine-3-yl-amine compounds as medicaments |
| 01/02/2004 | EP1372641A1 Enteral formulation |
| 01/02/2004 | EP1372634A2 Fumaric acid amides |
| 01/02/2004 | EP1372632A1 Proliferative activator receptor (ppar) compounds |
| 01/02/2004 | EP1372627A1 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases |
| 01/02/2004 | EP1372625A1 Uses of benzylideneamino guanidines as ligands to the melanocortiin receptors |
| 01/02/2004 | EP1372621A1 Novel use of tyrosine kinase inhibitor |
| 01/02/2004 | EP1372618A1 Colloidal suspension of nanoparticles based on an amphiphilic copolymer |
| 01/02/2004 | EP1372617A2 Enteric ketoacid salts and amino acids and their use for preparing medicines |
| 01/02/2004 | EP1372616A2 A stable pharmaceutical composition of pravastatin |
| 01/02/2004 | EP1372412A2 Composition improving age-related physiological deficits and increasing longevity |
| 01/02/2004 | EP1372411A1 Low glycemic response compositions |
| 01/02/2004 | EP1250146B1 Use of botulinum toxins for treating diabetes |
| 01/02/2004 | EP1235830B1 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS PROTEIN KINASES INHIBITORS |
| 01/01/2004 | US20040003425 Nav2 channel gene-deficient non-human animals |
| 01/01/2004 | US20040003422 An expression cassette containing the proopiomelanocortin (POMC) enhancer, and a nucleic acid sequence encoding POMC contains at least one exon, wherein a polylinker having an unique site for restriction enzyme is inserted into the exon; gene regulates weight and fat mass |
| 01/01/2004 | US20040002609 Antidiabetic agents; metabolism diseases; hypotensive agents; cardiovascular disorders |
| 01/01/2004 | US20040002537 Multiple sclerosis; central nervous system disorders; side effect reduction |
| 01/01/2004 | US20040002534 Stem cell factor; signal transduction passageways; anticancer agents |
| 01/01/2004 | US20040002533 Culture product of Streptomyces; lanosterol synthase inhibitor; anticholesterol agents, fungicides |
| 01/01/2004 | US20040002525 Obesity; osteoporosis |
| 01/01/2004 | US20040002524 Cardiovascular disorders; osteoporosis; central nervous system disorders |
| 01/01/2004 | US20040002519 Mixture of hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, insulin elimination promoter and insulin sensitizer with carrier |
| 01/01/2004 | US20040002512 Alpha-substituted carboxylic acid derivatives |
| 01/01/2004 | US20040002511 Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators |
| 01/01/2004 | US20040002501 Modulate signal transduction; antitumor, anticancer agents, vision defects, antidiabetic agents, antiinflammatory agents |
| 01/01/2004 | US20040002496 Compositions useful as inhibitors of protein kinases |
| 01/01/2004 | US20040002491 Melatonergic receptors |
| 01/01/2004 | US20040002490 Melatonergic receptors |
| 01/01/2004 | US20040002482 Androgen pharmaceutical composition and method for treating depression |
| 01/01/2004 | US20040002481 Novel 4-dedimethylaminotetracycline derivatives |
| 01/01/2004 | US20040002468 Methods of treating diabetes and other blood sugar disorders |
| 01/01/2004 | US20040002134 Novel nucleic acid sequences encoding human KIAA0768 protein-like and human protein PRO228-like polypeptides |
| 01/01/2004 | US20040002114 Nucleic acids encoding a G-protein coupled receptor involved in islet cell signaling |
| 01/01/2004 | US20040002113 Detection and treatment methods for type I diabetes |
| 01/01/2004 | US20040001898 Fermentated dietetic fibers; anticancer agents |
| 01/01/2004 | US20040001895 Combination treatment for depression and anxiety |
| 01/01/2004 | US20040001875 Antidiabetic agents; controlling concentration of protein, carbohydrates, fats |
| 12/31/2003 | WO2004001424A1 Materials and methods for inductions of immune tolerance |
| 12/31/2003 | WO2004001410A1 Methods for identifying glucose uptake modulators |
| 12/31/2003 | WO2004001053A1 β-GLUCAN-CONTAINING FAT COMPOSITIONS AND NOVEL MICROORGANISM PRODUCING β-GLUCAN |
| 12/31/2003 | WO2004001022A1 Probiotic propionibacterium jensenii 702 |